Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 633 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Birmingham, AlabamaAges 55–80 - NCT05973448Enrolling by invitation
Nightlight Falls Prevention for People With Dementia
This study tests a simple plan to help prevent falls in people who have dementia. You may be able to join if you live in a participating assisted living community and meet the safety and room rules.
Chapel Hill, North CarolinaAges 18 years+ - NCT05882344Enrolling by invitation
Deep brain stimulation for early Alzheimer’s memory problems
This trial tests whether a targeted deep brain stimulation treatment can help people with early Alzheimer’s disease symptoms and memory loss. It also involves brain imaging and a surgery/anesthesia procedure to place the stimulator.
Nashville, TennesseeAges 60–80 - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
Phoenix, ArizonaAges 35–85 - NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
Washington D.C., District of ColumbiaAges 55 years+ - NCT03657732Recruiting
Study of inherited Alzheimer’s genes in families
This study looks at people from families with inherited Alzheimer’s disease, including those who may be cognitively normal. It uses medical checkups and brain/nerve tests to better understand Alzheimer’s risk and symptoms in families with specific gene changes.
Hefei, AnhuiAges 18 years+ - NCT03653156Recruiting
Aging and brain study for mild memory loss and dementia
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
Hefei, AnhuiAges 18 years+ - NCT00064870Recruiting
Alzheimer's Disease Family Genetics Study
This study collects biological samples (blood or cells) from families where two or more members have been diagnosed with Alzheimer's disease or dementia. Researchers use these samples to identify genetic factors that may cause or increase risk for these conditions.
Nationwide, IndianaAges 18 years+ - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Chandler, ArizonaAges 55–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT07875998Recruiting
Blood markers and symptoms in probable Alzheimer's dementia
This study looks at people with probable Alzheimer's disease to see how certain blood biomarkers relate to their symptoms. It may help doctors better understand the disease and tailor care.
Tianjin, Tianjin MunicipalityAges 55–90 - NCT03019757Recruiting
Testing ways to tell dementia causes apart
This study looks at how to distinguish Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease when someone has memory and thinking problems. It may help doctors choose the most accurate diagnosis and treatment path for the right condition.
Columbus, OhioAges 18 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT02800395Recruiting
Study links brain changes to diet and blood markers in Alzheimer’s
This study looks at how diet-related and blood “stress” markers relate to how thinking and memory decline over time in people with Alzheimer’s. It may help researchers find useful biomarkers to better track progression and guide future care.
Pierre-BéniteAges 55 years+ - NCT03082755RecruitingPhase 4
Study sleep agitation and restless legs in Alzheimer’s patients
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
Austin, TexasAges 55 years+ - NCT05597410Recruiting
Study of people at risk for Alzheimer’s in Shanghai
This study follows people who are closely related to someone diagnosed with Alzheimer’s to see who develops memory or brain changes over time. It may help researchers understand risk and early signs, which could guide prevention in families like yours.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT05315895Recruiting
Study of people with “dampness” signs in Chinese medicine
This is an observational study that looks at a Chinese-medicine pattern called “dampness” by collecting health and biological information from volunteers. It may help researchers better understand what this pattern looks like and how it relates to people’s health.
Guangzhou, GuangdongAges 35–79 - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT05187819Recruiting
Blood test to help diagnose possible Alzheimer’s
This trial checks whether a simple blood test can help doctors diagnose Alzheimer’s in people who seem to have memory problems. If you’re being evaluated for possible dementia, your doctor may refer you to a memory clinic for testing and follow-up.
StavangerAges 40–100 - NCT05984524Recruiting
Gamma music therapy for mild Alzheimer's disease
This study tests whether a specially designed music intervention can help people with mild Alzheimer's disease. You listen to music with a gamma frequency beat, which may improve brain function and memory.
Boston, MassachusettsAges 50–95 - NCT05194787Recruiting
Online tests to spot early Alzheimer’s changes
This study looks at whether online motor (movement) and thinking tasks can detect early changes related to Alzheimer’s disease. You may be able to take part if you’re over 50 and do not already have a diagnosis of dementia.
Hobart, TasmaniaAges 50 years+ - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 633 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.